RaQualia Pharma Inc. (4579) Earnings Report: Net Sales Decrease 5.2% YoY to 1.455 Billion Yen with Operating Loss of 338 Million Yen

RaQualia Pharma Inc. (4579) has released its latest financial results, reporting net sales of 1,455 million yen, representing a 5.2% decrease compared to the same period of the previous year. On the profit front, the company posted an operating loss of 338 million yen, an ordinary loss of 326 million yen, and a net loss attributable to owners of the parent of 466 million yen. Earnings per share (EPS) stood at -18.1 yen. From a balance sheet perspective, the company maintains a relatively solid financial foundation with an equity ratio of 70.6%. Cash and cash equivalents stood at 4.70 billion yen, while interest-bearing debt was recorded at 2.69 billion yen and retained earnings at 230 million yen. Regarding cash flows, operating cash flow was -350 million yen and free cash flow was -230 million yen, reflecting the ongoing investment phase typical of a research-and-development-driven biopharmaceutical company.